TICKERNERD
Menu
MDLNHealthcare · Medical Instruments & Supplies

MDLN Stock Forecast: Medline, Inc. Price Predictions for 2026-2027

Last close, 3 Aug 2026
$40
+3.03% on the day

The 26 Wall Street analysts covering Medline, Inc. hold a median 12-month price target of $52 — +28.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 9 of 100 as at 1 Aug 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$70.0B
Ticker Nerd rank
9 / 100
Median analyst target
$52
Analysts covering
26
Total return, dividends reinvested
1W
+1.9%
1M
−6.3%
YTD
−3.6%
From high
−19.0%
From low
+21.9%
$33
$50
Range since 17 Dec 2025, adjusted closes · the dot is the last close
Ticker Nerd rank

MDLN stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Medline, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 1 Aug 2026
9 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Revisions
64
Issuance
64
Value
37
Growth
33
Accruals
19
Quality
18
Size
5
Momentum
3
Volatility
1

Revisions (64): Analysts have, on balance, been raising their forecasts.

Volatility (1): The share price moves around a lot.

The rank is the raw material. Whether the rules would actually own Medline, Inc. — and when they’d sell — is the membership.

Wall Street

MDLN stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on MDLN, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, since 17 Dec 2025Adjusted close, US dollars
$30$35$40$45$50$55$60$65Jan 26Apr 26Jul 26MDLNHigh $62Median $52Low $40

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says26 analysts
22 Buy4 Hold0 Sell
Low $40Median $52High $62

The green dot is the last close — the median target sits +28.5% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
31 July 2026BTIGReiteratesBuy$55
3 June 2026BairdMaintainsOutperform$57 → $45
1 June 2026BarclaysMaintainsOverweight$50 → $45
14 May 2026BNP ParibasMaintainsNeutral—
13 May 2026Tigress FinancialMaintainsBuy—
7 May 2026BernsteinMaintainsOutperform—
7 May 2026BTIGReiteratesBuy—
7 May 2026CitigroupMaintainsBuy—
11 Mar 2026CitigroupReinstatesBuy$60
10 Mar 2026JP MorganMaintainsOverweight—
9 Mar 2026BTIGReiteratesBuy—
9 Mar 2026Tigress FinancialMaintainsBuy—
2 Mar 2026Morgan StanleyMaintainsOverweight—
27 Feb 2026Wells FargoMaintainsEqual-Weight—
26 Feb 2026BMO CapitalMaintainsOutperform—
26 Feb 2026CitigroupMaintainsBuy—
26 Feb 2026Evercore ISI GroupMaintainsOutperform—
26 Feb 2026RBC CapitalMaintainsOutperform—
26 Feb 2026UBSMaintainsBuy—
5 Feb 2026Tigress FinancialInitiatesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Estimates

MDLN analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
+2.9%
Analysts raising
1
Analysts cutting
1
Fundamentals

Medline, Inc. (MDLN) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
35.7×

Cheaper than 23% of US stocks

Price / sales
2.5×

Cheaper than 47% of US stocks

Price / book
3.1×

Cheaper than 33% of US stocks

EV / EBITDA
17.0×

Cheaper than 20% of US stocks

Growth & margins
Revenue growth (YoY)
10.7%

Higher than 57% of US stocks

Earnings growth (YoY)
−59.9%

Higher than 8% of US stocks

Gross margin
25.0%

Higher than 29% of US stocks

Operating margin
5.4%

Higher than 58% of US stocks

Net margin
3.3%

Higher than 56% of US stocks

Returns & dividend
Return on equity
6.1%

Higher than 55% of US stocks

Return on assets
3.0%

Higher than 66% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

MDLN vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Instruments & Supplies
CompanyMarket capTKN rank
MDLNMedline, Inc.$70.0B
9
BDXBecton, Dickinson & Co.$45.6B
95
ALCAlcon AG$34.4B
59
RMDResMed, Inc.$30.8B
81
WSTWest Pharmaceutical Services, Inc.$24.5B
94
ISRGIntuitive Surgical, Inc.$126.7B
77
SOLVSolventum Corp.$14.8B
93
Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. MDLN appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

News

Latest MDLN news & analysis

Kaplan Fox is Investigating Medline Inc. (MDLN) for Potential Securities Law Violations - Investors Encouraged to Contact the Firm

Newsfile Corp · 3 Aug 2026negative

Kaplan Fox & Kilsheimer LLP is investigating potential securities law violations against Medline Inc. The firm is encouraging investors who have suffered losses or have relevant information to contact them.

Why it matters — The investigation signals potential legal and regulatory exposure for Medline that could affect the company's reputation and financial standing.

Kaplan Fox & Kilsheimer LLP Alerts Investors of Medline Inc. (MDLN) to an Investigation of Potential Securities Law Violations

Newsfile Corp · 31 July 2026negative

Kaplan Fox & Kilsheimer LLP announced it is investigating potential securities law violations against Medline Inc. (NASDAQ: MDLN) and is seeking information from investors who have suffered losses.

Why it matters — The investigation signals possible legal or regulatory trouble for Medline, which could affect the company's reputation and stock performance.

Kaplan Fox & Kilsheimer LLP Announces an Investigation into Medline Inc. (MDLN) for Possible Securities Law Violations

Newsfile Corp · 27 July 2026negative

Kaplan Fox & Kilsheimer LLP has announced an investigation into Medline Inc. for possible securities law violations, and is seeking information from investors who have suffered losses.

Why it matters — An investigation into potential securities law violations could lead to regulatory action or litigation, creating uncertainty for Medline shareholders.

FAQ

Frequently asked questions about MDLN stock

What is the MDLN stock price forecast for 2026-2027?

The 26 Wall Street analysts covering Medline, Inc. have a median 12-month price target of $52, with estimates ranging from $40 to $62. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is MDLN stock a buy right now?

Of the 26 analysts covering Medline, Inc., 22 rate it a Buy, 4 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Medline, Inc. 9 out of 100 across roughly 4,600 US stocks as at 1 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank MDLN?

As at 1 Aug 2026, Medline, Inc. ranks 9 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Revisions (64 of 100).

Will MDLN stock go up?

No one can know that. What the data says: the median 12-month target from 26 analysts implies +28.5% from the last close, and Ticker Nerd's factor model ranks Medline, Inc. 9 out of 100 as at 1 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the MDLN stock forecast for 2030?

No analyst covering Medline, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for MDLN are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $40 to $62 over the next 12 months.

What does Medline, Inc. do?

Medline Inc. is a healthcare company that provides medical-surgical products and supply chain solutions to healthcare providers.

What is the latest news on MDLN?

The most recent item we track (Newsfile Corp, 3 Aug 2026): "Kaplan Fox is Investigating Medline Inc. (MDLN) for Potential Securities Law Violations - Investors Encouraged to Contact the Firm". Kaplan Fox & Kilsheimer LLP is investigating potential securities law violations against Medline Inc. The firm is encouraging investors who have suffered losses or have relevant information to contact them.

Company

About Medline, Inc.

Medline Inc. is a healthcare company that provides medical-surgical products and supply chain solutions to healthcare providers. The company focuses on serving hospitals, surgery centers, physician offices, laboratories, and post-acute care facilities with a broad portfolio of consumable medical products, including surgical and procedural kits, gloves and protective apparel, urological and incontinence care items, wound care products, and lab and diagnostic supplies. Medline operates through two main segments: Medline Brand, which covers the procurement and manufacture of its own med-surg product lines, and Supply Chain Solutions, which delivers logistics, distribution, and inventory management services tailored to large healthcare systems. Headquartered in Northfield, Illinois, Medline positions itself as a key partner for healthcare institutions seeking to improve clinical, operational, and financial outcomes through reliable product availability, extensive branded offerings, and integrated supply chain capabilities in the medical-surgical space.

CEO Mr. James M. Boyle · 45,000 employees · United States · https://www.medline.com